Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial
The University of Texas MD Anderson Cancer Center · Houston Methodist
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
252
total citations
- FWCI
- 31.85
- Percentile
- 100%
- References
- 35
Citations per year
Authors
29- AOAhmed O. KasebCorresponding
- EHElshad Hasanov
The University of Texas MD Anderson Cancer Center
- HSHop Sanderson Tran Cao
The University of Texas MD Anderson Cancer Center
- LXLianchun Xiao
The University of Texas MD Anderson Cancer Center
- JVJean‐Nicolas Vauthey
The University of Texas MD Anderson Cancer Center
Topics & keywords
Topics
Keywords
- Nivolumab
- Medicine
- Ipilimumab
- Open label
- Perioperative
- Hepatocellular carcinoma
- Internal medicine
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.